The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment

Author： Lima-Rodrigues Manuel   Lamas Nuno   Valle-Fernandes Ana   Cruz Andrea   Vieira Artur   Oliveira Pedro   Pedrosa Jorge   Castro António   Reis Rui   Baltazar Fátima   Almeida Armando  

Publisher： Springer Publishing Company

ISSN： 1023-3830

Source： Inflammation Research, Vol.59, Iss.9, 2010-09, pp. : 743-753

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor

By Patrignani Paola   Capone Marta L   Tacconelli Stefania  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 2, 2003-02 ,pp. : 265-284

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3)

By  

Drug Metabolism Letters, Vol. 5, Iss. 2, 2011-04 ,pp. : 137-140

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-inflammatory therapy with a COX-2 inhibitor in Tourette's syndrome

By Müller Norbert  

Inflammopharmacology, Vol. 12, Iss. 3, 2004-01 ,pp. : 271-275

VSP

Access to resources Recommend Favorite

Etodolac (Lodine ® ): Profile of an established selective COX-2 inhibitor

By Jones Richard A.  

Inflammopharmacology, Vol. 9, Iss. 1-2, 2001-05 ,pp. : 63-70

VSP

Access to resources Recommend Favorite